688389 Shenzhen Lifotronic Technology Co., Ltd.
- 18.95
- -0.06-0.32%
Shenzhen Lifotronic Technology Co., Ltd. News
An Intrinsic Calculation For Shenzhen Lifotronic Technology Co., Ltd. (SHSE:688389) Suggests It's 27% Undervalued
Key Insights Using the 2 Stage Free Cash Flow to Equity, Shenzhen Lifotronic Technology fair value estimate is CN¥26.77 Shenzhen Lifotronic Technology's CN¥19.48 share price signals that it might be
Shenzhen Lifotronic Technology Co., Ltd.'s (SHSE:688389) Market Cap Increased by CN¥634m, Insiders Receive a 46% Cut
Key Insights Insiders appear to have a vested interest in Shenzhen Lifotronic Technology's growth, as seen by their sizeable ownership 53% of the business is held by the top 6 shareholders 23% of
Pumen Technology (688389.SH)'s net profit of 107 million yuan in the first quarter increased 21.69% year-on-year
On April 25, GLONGHUI (688389.SH) announced that in the first quarter of 2024, the company's revenue was 306 million yuan, up 10.06% year on year; net profit attributable to shareholders of listed companies was 107 million yuan, up 21.69% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 103 million yuan, up 24.60% year on year.
Pumen Technology (688389.SH) will distribute 2.81 yuan for every 10 shares in 2023. The stock registration date is April 30
Zhitong Finance App News, Pumen Technology (688389.SH) announced that the company will implement the 2023 equity distribution and distribute cash dividends of 2.81 yuan (tax included) to all shareholders for every 10 shares. The share registration date is April 30.
Take Care Before Diving Into The Deep End On Shenzhen Lifotronic Technology Co., Ltd. (SHSE:688389)
With a price-to-earnings (or "P/E") ratio of 23.6x Shenzhen Lifotronic Technology Co., Ltd. (SHSE:688389) may be sending bullish signals at the moment, given that almost half of all companies in China
Pumen Technology (688389.SH): Net profit in 2023 increased 30.66% year-on-year to 329 million yuan, and plans to distribute 10 to 2.81 yuan
On March 21, Ge Longhui (688389.SH) released its 2023 annual report. During the reporting period, it achieved operating income of 1,146 million yuan, an increase of 16.55%; net profit attributable to shareholders of listed companies of 329 million yuan, an increase of 30.66% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss of 313 million yuan, an increase of 34.39% year on year; and basic earnings per share of 0.77 yuan. In 2023, the company plans to distribute profits based on the total share capital registered on the equity registration date of implementation of equity distribution, and plans to distribute cash dividends to all shareholders for every 10 shares to the people
Declining Stock and Solid Fundamentals: Is The Market Wrong About Shenzhen Lifotronic Technology Co., Ltd. (SHSE:688389)?
It is hard to get excited after looking at Shenzhen Lifotronic Technology's (SHSE:688389) recent performance, when its stock has declined 16% over the past three months. But if you pay close attenti
Pumen Technology (688389.SH) Performance Report: 2023 net profit of 327 million yuan, up 30.21% year-on-year
GLONGHUI, Feb. 22丨Pumen Technology (688389.SH) announced the 2023 Annual Results Report. In 2023, the company achieved total operating revenue of 1,146 million yuan, an increase of 16.55%; realized net profit attributable to owners of the parent company of 327 million yuan, an increase of 30.21% year on year; realized net profit of 315 million yuan after deducting non-recurring profit and loss attributable to owners of the parent company, an increase of 34.88% year on year. The main reason for the increase in the company's performance during the reporting period: First, the revenue of the company's two main business lines of treatment and rehabilitation and in vitro diagnosis continued to grow. Treatment and Rehabilitation Business Connect
These 4 Measures Indicate That Shenzhen Lifotronic Technology (SHSE:688389) Is Using Debt Safely
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says 'The biggest investment risk is not the volatility of prices, but whether you will
Pumen Technology (688389.SH): The company's intense pulsed light therapy device (commonly known as “MM Light”) was launched at the end of November 2023
On January 30, Ge Longhui (688389.SH) said when surveyed by specific subjects, that the company's intense pulsed light therapy device (commonly known as “MM light”) was launched at the end of November 2023. Currently, the product is still in the marketing stage. Some regions have already signed contracts with agents. Judging from the current marketing situation, the market feedback is quite good. Next, we will continue to improve the product's operating plan through board promotion and channel expansion, while increasing investment in marketing. Currently, the company combines three specialty products into the “Three Great Anti-Aging” (i.e. “Cold Latining+Ultrasound V Latin America+
Pumen Technology (688389.SH): The company's international business is expected to achieve steady growth in the future
On January 30, Ge Longhui | When surveyed by specific subjects, Pumen Technology (688389.SH) said that under the premise of a stable international environment, domestic medical device companies all have relatively good market opportunities in export business, and business opportunities in the international market also mainly come from domestic import substitution. In terms of international business, the company divides the market into six regions. Every year, it will make some adjustments and expansions according to the specific situation in each region, and the development of each region is more balanced. The international marketing system team has stable personnel, and the division of tasks and goals in each region is quite clear. The company has already set up subsidiaries in Russia and Indonesia, and will be in the future
Pumen Technology (688389.SH): The company is developing a medium speed light emitting instrument
On January 30, Ge Longhui | Pumen Technology (688389.SH) said during a survey of specific subjects that the company's small light-emitting instrument terminal customers are mainly positioned as specialty projects in hospitals, emergency care, and small laboratories. Sales of luminescence instruments in the international market are mainly based on small luminescence. As the domestic installation of Luminescence Instruments is on the right track, the company has also begun to ship large luminescence instruments and their supporting reagents to the international market; at the same time, the company is developing medium speed luminescence instruments to further improve the serialization of the company's light-emitting instrument products.
Pumen Technology (688389.SH): The company's international business is mainly in vitro diagnosis business, and treatment and rehabilitation business does not account for a high proportion of export business
On January 30, Ge Longhui | When surveyed by specific subjects, Pumen Technology (688389.SH) said that the company's international business is mainly in vitro diagnosis business, and treatment and rehabilitation business does not account for a high proportion of export business. In the international in vitro diagnostic business, glycation accounts for the highest share of revenue, followed by luminescence.
Insiders Are the Top Stockholders in Shenzhen Lifotronic Technology Co., Ltd. (SHSE:688389), and the Recent 8.6% Drop Might Have Disappointed Them
Key Insights Shenzhen Lifotronic Technology's significant insider ownership suggests inherent interests in company's expansion The top 6 shareholders own 53% of the company Institutions own 25% o
SDIC Securities: Leading companies related to domestic IVD speeding up overseas development to build a second growth engine are expected to seize the opportunity
Going overseas is of great significance in increasing the development space of enterprises and extending the stage of rapid development of performance.
China Investment Securities: Domestic IVD accelerates overseas expansion to build a second growth engine
With the advancement of policies such as collection, domestic brands are expected to accelerate the increase in domestic market share. From a longer-term perspective, fully entering overseas markets is a necessary step for the domestic IVD industry to further open up room for growth and extend the stage of rapid development.
Pumen Technology (688389.SH): In the first three quarters of 2023, the main medical and aesthetic products “Cold Lift” and “Ultrasound V Latin America” had good feedback from end customers
Gelonghui, January 16丨According to the disclosure of investor relations activity records by Pumen Technology (688389.SH), compared to the previous two years, many medical and aesthetic institutions have already begun to resume marketing activities in the first half of 2023. Judging from the company's participation in the Meavos International Medical Aesthetic Conference, medical and aesthetic manufacturers from all over the country actively participated in the exhibition, and there were many visitors. In the first three quarters of 2023, the company's main medical and aesthetic products “Cold Lift” and “Ultrasound V Latin America” had good feedback from terminal customers; judging from sales data, the sales situation of the products basically met the company's expectations, and overall sales progressed smoothly.
Insufficient Growth At Shenzhen Lifotronic Technology Co., Ltd. (SHSE:688389) Hampers Share Price
When close to half the companies in China have price-to-earnings ratios (or "P/E's") above 35x, you may consider Shenzhen Lifotronic Technology Co., Ltd. (SHSE:688389) as an attractive investment with
The subsidiary of Pumen Technology (688389.SH) has received multiple medical device registration certificates
Pumen Technology (688389.SH) announced that Chongqing Pumenchuang Biotechnology Co., Ltd., a holding subsidiary of the company, recently...
Shenzhen Lifotronic Technology Co., Ltd. (SHSE:688389) Shares Could Be 36% Below Their Intrinsic Value Estimate
Key Insights Using the 2 Stage Free Cash Flow to Equity, Shenzhen Lifotronic Technology fair value estimate is CN¥36.32 Shenzhen Lifotronic Technology is estimated to be 36% undervalued based on cur
Analysis
Price Target
No Data
